by Richard Daverman, PhD
September 13, 2012 -- Two high-visibility generic drug JVs between east and west pharmas have commenced operations in China. Hisun Pharma and Pfizer have established their $295 million JV to produce branded generic drugs. At the same time, Merck and Simcere teamed up to concentrate on generic drugs for chronic ailments, especially cardiovascular and metabolic disease. Both were announced as letters of intent just over a year ago, and now they have become operational. More details....
Stock Symbols: (SHE: 600267) (NYSE: PFE) (NYSE: MRK) (NYSE SCR)
